CZE separation of new drugs for treatment of leukemia

J 2014

CZE separation of new drugs for treatment of leukemia

HORSKÁ, Jana, Pavlína GINTEROVÁ, Juraj ŠEVČÍK a Jan PETR

Základní údaje

Originální název

CZE separation of new drugs for treatment of leukemia

Název česky

CZE separace nových protinádorových léčiv na léčbu leukémie

Autoři

HORSKÁ, Jana, Pavlína GINTEROVÁ, Juraj ŠEVČÍK a Jan PETR

Vydání

Chromatographia, HEIDELBERG, SPRINGER, 2014, 0009-5893

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10406 Analytical chemistry

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.411

Organizační jednotka

Pedagogická fakulta

DOI

http://dx.doi.org/10.1007/s10337-014-2730-9

UT WoS

000345004800009

Klíčová slova anglicky

CHRONIC MYELOID-LEUKEMIA; CAPILLARY-ELECTROPHORESIS METHOD; ACUTE LYMPHOBLASTIC-LEUKEMIA; IMATINIB MESYLATE; KINASE INHIBITOR; DASATINIB; PAZOPANIB; CARCINOMA; ERLOTINIB

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 1. 2019 08:05, Dana Nesnídalová

Anotace

V originále

Imatinib, bosutinib, dasatinib, pazopanib, erlotinib, canertinib and vatalanib are new developed anticancer drugs, especially for treatment of leukemia. In this article, a fast and high throughput capillary zone electrophoresis method has been developed and validated for analysis of these new drugs in pharmaceutical formulas. The method can be easily utilized for determination of all the drugs in one run what is advantageous for the quality control in pharmaceutical industry because there is no need for changing and optimization of separation conditions when changing the analyte. The separation was performed using an uncoated fused silica capillary with 100 mmol L-1 sodium phosphate buffer pH 2.75, voltage of 25 kV, hydrodynamic injection time of 5 s by 50 mbar, and detection at 214 nm. Under these conditions, the analysis took about 8 min. The validation of all the drugs resulted in recoveries in the range of 84-100 %. The method showed to be precise for all the drugs with RSDs of migration times lower than 0.9 % (interday precision). A very good linearity in the validated range (5-100 mu g mL(-1)) and the limits of detection (LODs) in the range of 0.5-2.0 (mu g mL(-1)) were achieved. Finally, we proved that the method is robust by the Youden's test. Therefore, our method can be successfully applied for analysis of the real pharmaceutical samples.

Citovat

HORSKÁ, Jana, Pavlína GINTEROVÁ, Juraj ŠEVČÍK a Jan PETR. CZE separation of new drugs for treatment of leukemia. Chromatographia. HEIDELBERG: SPRINGER, 2014, roč. 77, 21-22, s. 1477-1482. ISSN 0009-5893. Dostupné z: https://dx.doi.org/10.1007/s10337-014-2730-9.

@article{1441417,
   author = {Horská, Jana and Ginterová, Pavlína and Ševčík, Juraj and Petr, Jan},
   article_location = {HEIDELBERG},
   article_number = {21-22},
   doi = {http://dx.doi.org/10.1007/s10337-014-2730-9},
   keywords = {CHRONIC MYELOID-LEUKEMIA; CAPILLARY-ELECTROPHORESIS METHOD; ACUTE LYMPHOBLASTIC-LEUKEMIA; IMATINIB MESYLATE; KINASE INHIBITOR; DASATINIB; PAZOPANIB; CARCINOMA; ERLOTINIB},
   language = {eng},
   issn = {0009-5893},
   journal = {Chromatographia},
   title = {CZE separation of new drugs for treatment of leukemia},
   volume = {77},
   year = {2014}
}

TY  - JOUR
ID  - 1441417
AU  - Horská, Jana - Ginterová, Pavlína - Ševčík, Juraj - Petr, Jan
PY  - 2014
TI  - CZE separation of new drugs for treatment of leukemia
JF  - Chromatographia
VL  - 77
IS  - 21-22
SP  - 1477-1482
EP  - 1477-1482
PB  - SPRINGER
SN  - 00095893
KW  - CHRONIC MYELOID-LEUKEMIA
KW  - CAPILLARY-ELECTROPHORESIS METHOD
KW  - ACUTE LYMPHOBLASTIC-LEUKEMIA
KW  - IMATINIB MESYLATE
KW  - KINASE INHIBITOR
KW  - DASATINIB
KW  - PAZOPANIB
KW  - CARCINOMA
KW  - ERLOTINIB
N2  - Imatinib, bosutinib, dasatinib, pazopanib, erlotinib, canertinib and vatalanib are new developed anticancer drugs, especially for treatment of leukemia. In this article, a fast and high throughput capillary zone electrophoresis method has been developed and validated for analysis of these new drugs in pharmaceutical formulas. The method can be easily utilized for determination of all the drugs in one run what is advantageous for the quality control in pharmaceutical industry because there is no need for changing and optimization of separation conditions when changing the analyte. The separation was performed using an uncoated fused silica capillary with 100 mmol L-1 sodium phosphate buffer pH 2.75, voltage of 25 kV, hydrodynamic injection time of 5 s by 50 mbar, and detection at 214 nm. Under these conditions, the analysis took about 8 min. The validation of all the drugs resulted in recoveries in the range of 84-100 %. The method showed to be precise for all the drugs with RSDs of migration times lower than 0.9 % (interday precision). A very good linearity in the validated range (5-100 mu g mL(-1)) and the limits of detection (LODs) in the range of 0.5-2.0 (mu g mL(-1)) were achieved. Finally, we proved that the method is robust by the Youden's test. Therefore, our method can be successfully applied for analysis of the real pharmaceutical samples.
ER  -

HORSKÁ, Jana, Pavlína GINTEROVÁ, Juraj ŠEVČÍK a Jan PETR. CZE separation of new drugs for treatment of leukemia. \textit{Chromatographia}. HEIDELBERG: SPRINGER, 2014, roč.~77, 21-22, s.~1477-1482. ISSN~0009-5893. Dostupné z: https://dx.doi.org/10.1007/s10337-014-2730-9.

Podrobný výpis o publikaci